• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Cost Savings and Increased Access With Ultra-Low-Dose Immunotherapy.

作者信息

Mitchell Aaron P, Goldstein Daniel A

机构信息

Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.

Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

出版信息

J Clin Oncol. 2023 Jan 10;41(2):170-172. doi: 10.1200/JCO.22.01711. Epub 2022 Oct 20.

DOI:10.1200/JCO.22.01711
PMID:36265102
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9839306/
Abstract
摘要

相似文献

1
Cost Savings and Increased Access With Ultra-Low-Dose Immunotherapy.超低剂量免疫疗法可节省成本并增加可及性。
J Clin Oncol. 2023 Jan 10;41(2):170-172. doi: 10.1200/JCO.22.01711. Epub 2022 Oct 20.
2
Potential cost savings by dose down-rounding of monoclonal antibodies in a community cancer center.社区癌症中心通过单克隆抗体剂量向下舍入实现潜在成本节约。
J Oncol Pharm Pract. 2018 Mar;24(2):116-120. doi: 10.1177/1078155217692400. Epub 2017 Feb 13.
3
Evaluation of the dosing strategies of biologic agents and the theoretical impact of dose rounding.生物制剂给药策略的评估及剂量取整的理论影响。
J Oncol Pharm Pract. 2018 Jan;24(1):47-55. doi: 10.1177/1078155216675518. Epub 2016 Oct 24.
4
Dose rounding of ipilimumab in adult metastatic melanoma patients results in significant cost savings.成年转移性黑色素瘤患者中，伊匹木单抗剂量的舍入可显著节省成本。
J Oncol Pharm Pract. 2014 Feb;20(1):47-50. doi: 10.1177/1078155213476723. Epub 2013 Mar 19.
5
Potential cost savings associated with dose rounding antineoplastic monoclonal agents.与抗肿瘤单克隆药物剂量舍入相关的潜在成本节约。
J Oncol Pharm Pract. 2015 Aug;21(4):280-4. doi: 10.1177/1078155214533369. Epub 2014 May 12.
6
Cost-effectiveness analysis in health care.医疗保健中的成本效益分析。
Hosp Cost Manag Account. 1995 Jul;7(4):1-8.
7
The cost and safety of multidose use of palivizumab vials.帕利珠单抗多剂量小瓶的成本与安全性。
Clin Pediatr (Phila). 2008 Mar;47(2):160-3. doi: 10.1177/0009922807306994. Epub 2007 Sep 27.
8
Optimising treatment for Australian melanoma patients can save taxpayers millions of dollars annually.优化澳大利亚黑色素瘤患者的治疗方案每年可为纳税人节省数百万美元。
Med J Aust. 2015 Feb 16;202(3):130. doi: 10.5694/mja14.01202.
9
Allergy immunotherapy: what is the evidence for cost saving?过敏免疫疗法：节省成本的证据有哪些？
Curr Opin Allergy Clin Immunol. 2014 Aug;14(4):363-70. doi: 10.1097/ACI.0000000000000084.
10
The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries.利妥昔单抗生物类似药CT-P10在风湿病学和肿瘤学中的应用：28个欧洲国家的预算影响分析
Adv Ther. 2017 May;34(5):1128-1144. doi: 10.1007/s12325-017-0522-y. Epub 2017 Apr 10.

引用本文的文献

1
Constructing the cure: engineering the next wave of antibody and cellular immune therapies.构建治愈方法：打造下一代抗体和细胞免疫疗法。
J Immunother Cancer. 2025 Aug 25;13(8):e011761. doi: 10.1136/jitc-2025-011761.
2
The Complexity of Malignant Glioma Treatment.恶性胶质瘤治疗的复杂性
Cancers (Basel). 2025 Mar 4;17(5):879. doi: 10.3390/cancers17050879.
3
A phase II, randomized, open-labeled study to evaluate low-dose pembrolizumab in addition to neoadjuvant chemotherapy for triple-negative breast cancer (TNBC).一项II期随机开放标签研究，旨在评估低剂量帕博利珠单抗联合新辅助化疗用于三阴性乳腺癌（TNBC）的疗效。
Trials. 2025 Feb 27;26(1):73. doi: 10.1186/s13063-025-08726-9.
4
India's Potential as a Leader in Cancer Care Progress in the Future: A Synthetic Interdisciplinary Perspective.印度在癌症护理领域未来成为领导者的潜力：一个综合性跨学科视角
Cureus. 2024 Oct 5;16(10):e70892. doi: 10.7759/cureus.70892. eCollection 2024 Oct.
5
Using context-specific evidence to inform resource-stratified cancer guidelines: A call for a new approach.利用特定背景证据为资源分层癌症指南提供信息：呼吁采用新方法。
Cancer. 2025 Jan 1;131(1):e35573. doi: 10.1002/cncr.35573. Epub 2024 Sep 22.
6
Novel Effective Therapeutic Regimen for Recurrent/Metastatic Head and Neck Squamous Cell Cancer: Concurrent Triple Oral Metronomic Chemotherapy and Immunotherapy.复发性/转移性头颈部鳞状细胞癌的新型有效治疗方案：三联口服节拍化疗与免疫治疗同步进行
J Immunother Precis Oncol. 2024 Aug 19;7(3):171-177. doi: 10.36401/JIPO-24-1. eCollection 2024 Aug.
7
Case report: Is severe toxicity the price to pay for high sensitivity to checkpoint inhibitors immunotherapy in desmoplastic melanoma?病例报告：间皮素阳性黑色素瘤患者对免疫检查点抑制剂高度敏感是否会导致严重毒性？
Front Immunol. 2024 May 10;15:1369531. doi: 10.3389/fimmu.2024.1369531. eCollection 2024.
8
Antiangiogenic-immune-checkpoint inhibitor combinations: lessons from phase III clinical trials.抗血管生成-免疫检查点抑制剂联合治疗：III 期临床试验的经验教训。
Nat Rev Clin Oncol. 2024 Jun;21(6):468-482. doi: 10.1038/s41571-024-00886-y. Epub 2024 Apr 10.
9
Severe autoimmune hemolytic anemia following immunotherapy with checkpoint inhibitors in two patients with metastatic melanoma: a case report.两名转移性黑色素瘤患者接受免疫检查点抑制剂治疗后发生严重自身免疫性溶血性贫血：病例报告。
Front Immunol. 2024 Mar 20;15:1342845. doi: 10.3389/fimmu.2024.1342845. eCollection 2024.
10
An Ailment with Which I Will Contend: A Narrative Review of 5000 Years of Esophagogastric Cancers and Their Treatments, with Special Emphasis on Recent Advances in Immunotherapeutics.我将应对的一种疾病：对5000年食管癌和胃癌及其治疗方法的叙述性综述，特别强调免疫治疗的最新进展。
Cancers (Basel). 2024 Jan 31;16(3):618. doi: 10.3390/cancers16030618.

本文引用的文献

1
Low-Dose Immunotherapy in Head and Neck Cancer: A Randomized Study.头颈部癌的低剂量免疫疗法：一项随机研究。
J Clin Oncol. 2023 Jan 10;41(2):222-232. doi: 10.1200/JCO.22.01015. Epub 2022 Oct 20.
2
Price changes and within-class competition of cancer drugs in the USA and Europe: a comparative analysis.美国和欧洲癌症药物的价格变化与同类产品竞争：一项比较分析。
Lancet Oncol. 2022 Apr;23(4):514-520. doi: 10.1016/S1470-2045(22)00073-0. Epub 2022 Mar 7.
3
Improving access to immunotherapy in low- and middle-income countries.改善低收入和中等收入国家获得免疫疗法的机会。
Ann Oncol. 2022 Apr;33(4):360-361. doi: 10.1016/j.annonc.2022.01.003. Epub 2022 Jan 13.
4
Pharmacokinetic Simulation Analysis of Less Frequent Nivolumab and Pembrolizumab Dosing: Pharmacoeconomic Rationale for Dose Deescalation.更频繁地使用纳武利尤单抗和帕博利珠单抗剂量的药代动力学模拟分析：剂量下调的药物经济学原理。
J Clin Pharmacol. 2022 Apr;62(4):532-540. doi: 10.1002/jcph.1984. Epub 2022 Jan 5.
5
Near-Equivalence: Generating Evidence to Support Alternative Cost-Effective Treatments.近似等效性：生成支持替代成本效益治疗方法的证据。
J Clin Oncol. 2021 Mar 20;39(9):950-955. doi: 10.1200/JCO.20.02768. Epub 2021 Feb 8.
6
A Phase 2 Study of Nivolumab Using a Fixed Dose of 40 mg (Nivo40) in Patients With Relapsed/Refractory Hodgkin Lymphoma.一项针对复发/难治性霍奇金淋巴瘤患者使用40毫克固定剂量纳武单抗（Nivo40）的2期研究。
Hemasphere. 2020 Sep 23;4(5):e480. doi: 10.1097/HS9.0000000000000480. eCollection 2020 Oct.
7
Alternative dosing regimens for atezolizumab: right dose, wrong frequency.阿替利珠单抗的不同剂量方案：剂量正确，频率错误。
Cancer Chemother Pharmacol. 2019 Dec;84(6):1153-1155. doi: 10.1007/s00280-019-03971-7. Epub 2019 Oct 19.
8
Competition and price among brand-name drugs in the same class: A systematic review of the evidence.同类别品牌药物之间的竞争与价格：证据的系统评价。
PLoS Med. 2019 Jul 30;16(7):e1002872. doi: 10.1371/journal.pmed.1002872. eCollection 2019 Jul.
9
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.帕博利珠单抗对比甲氨蝶呤、多西他赛或西妥昔单抗用于治疗复发性或转移性头颈部鳞状细胞癌（KEYNOTE-040）：一项随机、开放标签、III 期研究。
Lancet. 2019 Jan 12;393(10167):156-167. doi: 10.1016/S0140-6736(18)31999-8. Epub 2018 Nov 30.
10
Time Is Money: Optimizing the Scheduling of Nivolumab.时间就是金钱：优化纳武单抗的给药计划
J Clin Oncol. 2018 Aug 27:JCO1800045. doi: 10.1200/JCO.18.00045.